Critical Checks for Pharmaceutical-Grade PaclitaxelProcurement
For oncology drug manufacturers, sourcinghigh-purity bulk paclitaxel requires rigorous verification. As a GMP-certifiedsupplier, Blue Eyes Biotech Co., Ltd. outlines key factors pharma buyers mustassess to avoid costly delays or compliance risks.
1.Purity & Analytical Documentation
- Demand ≥98% purity (HPLC-verified) with full chromatograms
- Require batch-specific Certificates ofAnalysis (CoA) including:
✓ Residual solvent levels (USP/EP limits)
✓ Related substances profile (e.g., cephalomannine, baccatinIII)
✓ Heavy metals & endotoxin testing (for injectableformulations)
2.Regulatory Compliance
- Verify Drug Master Files (DMF) or CEPsfor major markets (US/EU/China)
- Confirm GMP compliance with:
✓ FDA 21 CFR 210/211 (for US market)
✓ EU GMP Annex 1 (sterile products)
✓ WHO PQ certification (emerging markets)
3.Supply Chain Transparency
- Audit the supplier's:
✓ Taxus sourcing method (sustainable plant-cell fermentation preferred)
✓ CITES certification (if using natural yew extraction)
✓ Stability data (24-month minimum for API storage)
4.Formulation-Specific Properties
- For nanoparticle albumin-bound (nab)paclitaxel:
✓ Particle size distribution (D90 <200nm)
✓ Free vs. bound paclitaxel ratio
- For solvent-based formulations:
✓ Cremophor-free alternatives availability
WhyPharma Trusts Blue Eyes Biotech?
✔ FDA/EMA-approved manufacturing facility(audit reports available)
✔ End-to-end documentation from rawmaterial to finished API
✔ 50kg+ bulk quantities withnitrogen-packed stability assurance
Request Compliance Documentation:
Email: [email protected]
Website: www.blueeyes-bio.com